Digital Health Investors

What are Digital Health investors, and what do they look for?

Digital health sits on a line that matters legally as much as commercially: whether the software makes a clinical claim. Software that diagnoses, treats or informs a treatment decision is a regulated medical device in Europe, with conformity assessment, clinical evaluation and post-market obligations attached. Software that organises appointments, supports administration or offers general wellbeing content is not. Investors establish which side you are on before assessing anything else, because the answer changes the timeline and cost by years. Clinical integration is the second question. Products that require clinicians to work outside their existing systems fail regardless of quality, because the working day has no spare capacity. Investors ask how the product reaches the clinician, whether it appears inside the record system they already use, and what evidence exists that it saves time rather than adding a step. Third, they examine the payment route. Direct consumer payment is difficult in European markets where care is largely publicly funded, so the durable models involve reimbursement, health system procurement, insurer contracts or employer purchase. A product without one of those has an adoption story rather than a revenue model.

Why Digital Health is attracting investor interest

Reimbursement pathways for software appeared where none previously existed, and that changed what could be built as a business rather than a pilot. Several European systems now have defined routes for digital applications to be prescribed and paid for, with evidence requirements attached. The bar is demanding, and the existence of a codified process means a company can plan towards a known outcome rather than hoping for procurement. Capacity pressure supplies the demand. European health systems face workforce shortages and waiting lists that cannot be resolved by recruitment, which makes anything that moves care out of hospitals, triages more accurately or lets fewer staff manage more patients commercially interesting to the people who hold budgets. Remote monitoring matured from novelty into practice. Managing long-term conditions between appointments, using data collected at home, has moved into routine care in several countries because it demonstrably reduces admissions. Investors remain cautious about the consumer end. Direct-to-consumer health applications face high churn, limited willingness to pay in systems where care is free at the point of use, and stricter European rules on health claims than founders coming from other markets expect.

Which funding stages Digital Health investors are active at

Digital health funding follows evidence and payer milestones rather than user growth. Seed rounds fund product development and initial clinical partnerships, with investors weighing clinical credibility on the founding team heavily. A practising clinician involved substantively changes how a round is received. Series A generally requires clinical evidence and a defined payment route, whether a reimbursement listing, a health system contract or an insurer agreement. Companies with strong user numbers and no payer are the most common stall pattern in this category, since engagement without revenue does not scale into a business. Series B funds commercial scaling into health systems, which means procurement, information governance review and integration work per customer. Investors examine whether the second deployment took less effort than the first. Growth capital is thinner than in general software, and strategic acquirers include health system suppliers, insurers, pharmaceutical companies and medical device groups. Public and charitable funding for clinical validation is available across Europe and suits the evidence stage well.

Typical check and round sizes in Digital Health

Averages would blend regulated therapeutic software with unregulated administrative tools, whose costs differ by an order of magnitude, so the useful guidance is about what the capital must cover. For regulated products, the round has to fund clinical evaluation and conformity assessment before revenue is possible. Those timelines have been extended by capacity constraints in the European assessment system, and companies that budgeted on historical durations have run short. Build genuine contingency and expect investors to apply their own. For anything seeking reimbursement, the evidence requirements are specific and the assessment process takes time after the study concludes. Rounds should be sized to reach a reimbursement decision with margin, since arriving at the decision point with no runway leaves no capacity to respond to conditions or requests for further data. Information governance and security accreditation are prerequisites for selling into European health systems, and they cost money and time before any contract exists. Non-dilutive funding for clinical validation is substantial across national and European programmes, and companies that use it reach the same evidence position considerably less diluted. For comparables, use recent European rounds from companies with the same regulatory classification and payer model.

Types of investors active in Digital Health

What Digital Health investors look for in diligence

Digital health diligence draws on clinical and regulatory advisers, and it examines evidence more critically than software diligence does. Regulatory classification is assessed independently. Investors ask which rule applies, who advised on it, whether a notified body has been engaged, and what happens if a reviewer disagrees with your position. Products making implicit clinical claims while classified as wellness are identified quickly. Clinical evidence is examined for whether it supports the specific claim being made. Study design, comparator, endpoints and whether results were independently analysed all receive attention, and investors distinguish between engagement data and outcome data. Reimbursement position is verified: which pathway, which country, what stage of application, and what precedent exists for comparable products. Information governance is reviewed in detail, since health data is a special category under European data protection rules and health system contracts impose specific security and residency requirements. Clinical integration is tested by asking how the product connects to record systems and what proportion of deployments achieved that integration rather than running alongside. Usage among clinicians is examined separately from patient usage, because a product patients like and clinicians ignore does not survive contract renewal in a system where clinical opinion drives purchasing.

How to build a fundraising strategy as a Digital Health startup

Settle your regulatory classification early with documented advice, and design the evidence plan around the claim you intend to make. Retrofitting a clinical claim onto a product built as wellness is expensive and frequently requires starting the evidence work again. Identify the payer before building for the user. European digital health has produced many products with engaged users and no route to revenue, because care is publicly funded and consumers do not pay for what the system provides free. Naming the budget holder in your first slide filters the investor list usefully. Use non-dilutive funding for clinical validation. Public and charitable programmes across Europe fund exactly this work, and companies that combine grants with equity arrive at Series A owning materially more of the business. Design for clinical workflow rather than around it. Products that require clinicians to open another system have a ceiling, and integration with the existing record is the single most valuable engineering investment in this category. Get information governance and security accreditation done before you need them, since they gate health system sales entirely and take longer than founders expect. Sequence countries deliberately. Reimbursement routes, procurement practice and clinical culture differ enough that success in one European system is weak evidence for the next, and investors who know the sector will test whether you understand that.

Common mistakes founders make raising Digital Health capital

Describing a product as wellness while making claims that clearly imply clinical benefit is the error investors and regulators both punish. It reads as either uninformed or evasive, and neither impression is recoverable within a single process. Building for patients without a payer produces engagement metrics and no revenue. In European systems where care is free at the point of use, consumer willingness to pay is considerably lower than founders from other markets assume. Presenting engagement as outcome evidence misunderstands what health systems buy. Usage figures answer a different question from whether the product improved anything clinically measurable. Adding steps to the clinical day guarantees abandonment. Products that require a clinician to leave their record system are competing against a workload that has no slack in it. Underestimating information governance and procurement timelines leaves companies out of runway with contracts still progressing, which is the most common failure mode among otherwise sound digital health businesses. Assuming a reimbursement route in one country transfers to another is a costly misreading, since each system defines its own evidence requirements and assessment process.

How Digital Health investment differs across Europe

Germany established the most clearly codified route in Europe for digital health applications to be prescribed and reimbursed, with defined evidence requirements and a formal assessment process. That clarity has attracted considerable investor attention to German digital health specifically. The UK combines a single large public system with centralised evaluation frameworks, which makes national adoption slow to achieve and comprehensive once secured. Information governance requirements are demanding and well documented. France has substantial public investment in digital health, a national framework for reimbursed digital therapeutics and a large hospital network where adoption typically progresses regionally. The Nordics have the strongest digital infrastructure in European healthcare, with mature electronic records and population registries that make both integration and clinical evidence generation considerably easier than elsewhere. The Netherlands and Belgium combine high digital maturity with well-organised systems and predictable procurement, which makes them practical first markets. Southern and Central Europe generally have longer procurement cycles, tighter budgets and less developed digital infrastructure in public systems, though private healthcare in several of these markets adopts faster than the public sector does. Across all of them, information governance requirements are strict and differ in detail, so a product that satisfies one system still needs work to satisfy the next.